Latest Insider Transactions at Cyma Bay Therapeutics, Inc. (CBAY)
This section provides a real-time view of insider transactions for Cyma Bay Therapeutics, Inc. (CBAY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CymaBay Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CymaBay Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2024
|
Charles Mc Wherter President of R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,938
-100.0%
|
-
|
|
Mar 22
2024
|
Klara Dickinson Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,000
-100.0%
|
-
|
|
Mar 22
2024
|
Harish Shantharam Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,125
-100.0%
|
-
|
|
Mar 22
2024
|
Sujal Shah Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
406,670
-100.0%
|
-
|
|
Mar 22
2024
|
Robert James Wills |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,000
-100.0%
|
-
|
|
Mar 22
2024
|
Paul T Quinlan General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,262
-100.0%
|
-
|
|
Mar 22
2024
|
Kurt Von Emster |
SELL
Sale (or disposition) back to the issuer
|
Direct |
90,000
-100.0%
|
-
|
|
Mar 13
2024
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
41,824
+37.31%
|
$292,768
$7.89 P/Share
|
|
Mar 13
2024
|
Sujal Shah Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
139,119
+4.11%
|
$834,714
$6.1 P/Share
|
|
Feb 12
2024
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
6,000
-100.0%
|
$186,000
$31.97 P/Share
|
|
Feb 12
2024
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$24,000
$4.63 P/Share
|
|
Jan 24
2024
|
Charles Mc Wherter President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
31,938
+40.49%
|
-
|
|
Jan 24
2024
|
Klara Dickinson Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+50.0%
|
-
|
|
Jan 24
2024
|
Harish Shantharam Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,125
+50.0%
|
-
|
|
Jan 24
2024
|
Sujal Shah Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,250
+26.46%
|
-
|
|
Jan 24
2024
|
Paul T Quinlan General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
28,438
+50.0%
|
-
|
|
Jan 19
2024
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
18,403
-18.59%
|
$423,269
$23.67 P/Share
|
|
Jan 19
2024
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
18,403
+15.25%
|
$92,015
$5.26 P/Share
|
|
Jan 16
2024
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$115,000
$23.58 P/Share
|
|
Jan 16
2024
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Jan 16
2024
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$230,000
$23.58 P/Share
|
|
Jan 16
2024
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$40,000
$4.05 P/Share
|
|
Jan 10
2024
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
6,000
-100.0%
|
$138,000
$23.86 P/Share
|
|
Jan 10
2024
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$24,000
$4.63 P/Share
|
|
Dec 18
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
11,332
-27.3%
|
$237,972
$21.49 P/Share
|
|
Dec 18
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
11,332
+21.4%
|
$56,660
$5.0 P/Share
|
|
Dec 15
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$105,000
$21.98 P/Share
|
|
Dec 15
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Dec 15
2023
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
21,497
-100.0%
|
$451,437
$21.99 P/Share
|
|
Dec 15
2023
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
21,497
+50.0%
|
$128,982
$6.24 P/Share
|
|
Dec 11
2023
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
6,000
-100.0%
|
$120,000
$20.07 P/Share
|
|
Dec 11
2023
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$24,000
$4.63 P/Share
|
|
Dec 11
2023
|
Sujal Shah Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
64,865
-13.85%
|
$1,297,300
$20.4 P/Share
|
|
Dec 11
2023
|
Sujal Shah Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,865
+10.95%
|
$324,325
$5.0 P/Share
|
|
Nov 17
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
11,342
-43.06%
|
$204,156
$18.28 P/Share
|
|
Nov 17
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
11,342
+30.1%
|
$56,710
$5.0 P/Share
|
|
Nov 15
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$85,000
$17.38 P/Share
|
|
Nov 15
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Nov 15
2023
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
0
|
$0
$17.38 P/Share
|
|
Nov 15
2023
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+50.0%
|
$52,500
$3.45 P/Share
|
|
Nov 13
2023
|
Sujal Shah Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
64,863
-15.65%
|
$972,945
$15.89 P/Share
|
|
Nov 13
2023
|
Sujal Shah Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,863
+13.38%
|
$324,315
$5.0 P/Share
|
|
Nov 10
2023
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$105,000
$15.24 P/Share
|
|
Nov 10
2023
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$28,000
$4.63 P/Share
|
|
Oct 18
2023
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
21,743
-59.18%
|
$304,402
$14.07 P/Share
|
|
Oct 18
2023
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
21,743
+37.18%
|
$108,715
$5.0 P/Share
|
|
Oct 16
2023
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$65,000
$13.76 P/Share
|
|
Oct 16
2023
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
|
Oct 16
2023
|
Daniel Menold Vice President, Finance |
SELL
Open market or private sale
|
Direct |
0
|
$0
$13.76 P/Share
|
|
Oct 16
2023
|
Daniel Menold Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+50.0%
|
$52,500
$3.45 P/Share
|